Bayer's €2 Billion Hybrid Raise and Apollo-Backed Contraceptive Deal Reshape the Balance Sheet as Missouri Ruling Looms
Published on 09/26/2026 at 10:41 | Editorial boerse-global.de
Bayer has spent the past several weeks assembling the pieces of a financial and legal reset, and investors are now weighing whether the combination can finally put the worst of the group's troubles behind it. The Leverkusen-based agriculture and pharmaceutical company has pulled in fresh capital, struck a partnership with two heavyweight financial investors, and pushed forward on both the courtroom and regulatory fronts — all while its shares have mounted a striking recovery.
On the capital markets side, the most consequential move was a hybrid bond issue totaling €2 billion. That transaction lifts the outstanding volume of Bayer's hybrid instruments to €6.55 billion. Such securities sit between equity and debt, giving the company accounting headroom on its balance sheet while obligating it to fixed interest payments that will weigh on future earnings. The two tranches of the latest hybrid carry maturities of 30 years and coupons of 5.75% and 6.25% respectively — commitments that leave little flexibility if the agricultural division fails to deliver the hoped-for operating gains.
Alongside the bond sale, Bayer brought in outside equity for a newly founded entity that holds its long-acting reversible contraceptives. Two investors — Apollo and KKR — supplied the capital, but operational control stays entirely within the group. The structure marks a shift in how Bayer manages its resources without resorting to carving out whole divisions: external money strengthens the company's room to maneuver, while established cash flows remain under its operational grip. The arrangement does carry longer-term tensions, though. Apollo and KKR expect attractive returns from the contraceptive vehicle, and if growth in that segment falls short of expectations, the complex corporate structure could end up burdening the balance sheet rather than relieving it.
A Product Sale and a Regulatory First
Portfolio pruning has continued in parallel. Bayer agreed to sell its cancer drug Stivarga to Grünenthal for a total of up to €375 million. The disposal sheds an established single product and frees up funds for broader business development. Completion is targeted for late 2026 or early 2027, subject to regulatory approvals — making the deal's closing a milestone worth tracking on the operational calendar.
Should investors sell immediately? Or is it worth buying Bayer?
On the pharmaceutical pipeline, the company logged a notable win in the United States. More than a month ago, the FDA granted approval for Kerendia, whose active ingredient is finerenone, in adult patients with chronic kidney disease associated with type 1 diabetes. The decision followed an accelerated review. According to the company, it represents the first new approval in this specific indication in more than three decades.
Missouri Holds the Key
The single largest swing factor remains the legal front. Roughly two weeks ago, Bayer and its subsidiary Monsanto pressed a Missouri court to approve a settlement of $7.25 billion aimed at resolving tens of thousands of lawsuits over the herbicide Roundup. A favorable ruling would remove a paralyzing layer of uncertainty and let the pharmaceutical business supply fresh clinical momentum to the pipeline. Should the judge reject or delay the agreement, however, the litigation risk would swell again unchecked, tying up new equity and shaking institutional confidence once more.
Market participants treat the judicial resolution of these disputes as the decisive variable for the company's future predictability. If the settlement delivers the hoped-for legal calm, the discount tied to litigation could narrow and the earnings base would firm up noticeably — particularly if the Stivarga proceeds arrive on schedule and are used to retire expensive liabilities, allowing operating margins to recover and the stock to command valuation premiums again.
Shareholder Register Shifts
There was also movement in the ownership structure. On September 14, Amundi crossed the 3% reporting threshold, lifting its voting rights stake to 3.04%, according to media reports. Shifts of this kind draw investor attention because they reveal how larger addresses are positioning themselves — and this one landed during a phase in which Bayer is juggling multiple operational and strategic workstreams at once.
The Chart and the Two Dates That Matter
The shares closed Friday at €50.20, giving the DAX-listed stock a gain of 36% since the start of the year. Measured against its level twelve months ago, the advance reaches 84%. As long as the stock defends its elevated valuation and holds above its 200-day moving average of €42.80, the technical backdrop stays constructive, with the market pricing in a gradual cleanup of legacy burdens.
Two concrete dates now command attention. The first is the judge's decision on the $7.25 billion US settlement, which will define the legal framework. The second is the planned completion of the Stivarga sale to Grünenthal. Whether the restructuring holds together will be judged against those two tests — and every quarterly report in between will be measured first and foremost by the pace of debt reduction.
Ad
Bayer Stock: New Analysis - 26 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
